Loading clinical trials...
Loading clinical trials...
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine GSK2321138A When Administered in Children
Conditions
Interventions
Influenza vaccine GSK2321138A
FluarixTM
+1 more
Locations
59
United States
GSK Investigational Site
Sacramento, California, United States
GSK Investigational Site
Boca Raton, Florida, United States
GSK Investigational Site
Wichita, Kansas, United States
GSK Investigational Site
Wichita, Kansas, United States
GSK Investigational Site
Lexington, Kentucky, United States
GSK Investigational Site
Metairie, Louisiana, United States
Start Date
October 4, 2010
Primary Completion Date
June 15, 2011
Completion Date
June 15, 2011
Last Updated
September 21, 2018
NCT07291635
NCT06094010
NCT06417762
NCT06160128
NCT07396428
NCT07310472
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions